Member Info for Bella6532

F3...an RNS is a couple of hundred quid..

Avacta has always given notice of their upcoming Investor Meet Presentations..nothing new.

We have a bunch of Americans heading Avacta now...of course they will go for a dual listing.

Bringing David Bryant on board due to his senior advisory position with HCRx (which appears to still be in place after their recent takeover according to the Press Release I posted on here a few days ago) was all about finance. As was the case for bring Richard Hughes in too.

If HCRx want to do a Royalty deal with Avacta, they will do it on the back of a Commercial Deal with a Pharma...and will I'm sure want to see the NASDAQ Listing go ahead too. Not sure how the Bond debt and lack of income would affect NASDAQ Listing unless they do for a RTO.

Avacta will need to top up their coffers in H1 so the first half of 2026 is going to be very interesting.

Ceesor..you could say that about half the posts on here...lighten up hun...it's the season to be jolly...😘

Perhaps news will be forthcoming once buyers order has been filled...

05-Dec-25 15:20:48 78.69231 325,000 Buy* 255.75k O

Ceesor...that's the joke...we just don't know...hence my comments...'possibly' 'I could be wrong'...

LDA...next week...11th or 18th...or 30th with the Year End Business Update but most likely that will be in New Year when they're all back from their holidays so unlikely it will be on 30th...but I could be wrong.

LDA...we have all assumed a deal for AVA6900 would be with big Pharma..BUT what would be the net result for Avacta if they worked with the likes of Uniphar for AVA6000 only. You need to work this through with IP ownership in mind too.

'Uniphar | Global Sourcing

Expanding access, empowering innovation.

Strategic In-Licensing to bring pharmaceutical breakthroughs to market

At Uniphar | Global Sourcing, we unlock new market potential for pharmaceutical brands through strategic in-licensing partnerships. By bridging global innovation with local market access, we support both established and emerging pharma companies in expanding their reach efficiently and compliantly. From regulatory support to commercialization, we ensure that breakthrough therapies reach the patients who need them most.

Why In-Licensing is a solid approach:

Enables faster market access for pharmaceutical innovations.

Reduces risk and cost for companies entering new geographies.

Leverages local regulatory and distribution expertise for successful launches. '

Mmmm! Interesting....thoughts anyone...could they be of use to Avacta...???

https://www.uniphar.ie/static/services/uniphar-pharma/

'We are delighted to welcome David Bryant as he joins Uniphar as Board Advisor to our Pharma division.

David has a successful track record spanning global commercial leadership, corporate development, and investment roles. His career includes senior positions at GSK, Wyeth/Pfizer, and Clinigen, where he was part of the founding management team that led the company through its IPO, executed multiple product and corporate acquisitions, and ultimately supported its £1.6bn sale in 2022.

Today, David serves as a Senior Advisor to U.S.-based HealthCare Royalty, supporting investments across the UK and Europe, and as a Non-Executive Director at UK AIM-listed Avacta Therapeutics.

David brings a wealth global expertise and proven leadership and will play a pivotal role in guiding our strategic growth.

David will play a leading role in:

- Shaping strategy and market-entry models to ensure seamless pathways from clinical development to commercialization.

- Enhancing partner networks to bring medicines and technologies to more than 180 countries.

- Supporting high-value access, regulatory, and launch activities, enabling broader patient reach.

- Driving scalable growth through Uniphar’s end-to-end solutions.

Please join us in welcoming David to the Uniphar team – we’re thrilled to have him on board.'

See last page of the latest Presentation Deck on Avacta website where the 3 different IP sets are explained.

From 31 Dec 2024 Prelims

This unique platform has the potential to treat up to 90% of solid tumors by repurposing a range of effective oncology drugs to significantly reduce toxicity and side effects. This represents a potential breakthrough for patients and a major opportunity for Avacta.

“With our first program in the clinic, we expect to release the initial data in salivary gland cancer for FAP-Dox (AVA6000) towards the end of 2025 and in triple negative breast cancer in H1 2026 with potential for Phase 2 trials in H1 2026.

“FAP-EXd (AVA6103) has advanced into IND-enabling work this year and we plan to initiate the Phase 1 trial in early 2026. In parallel, we are actively pursuing a number of commercial opportunities.

“Overall, 2025 and 2026 are set to be a transformative for Avacta, driven by a number of catalysts to drive shareholder value.”

They will get a deal and it will come with upfront payment but more importantly it will most likely be the trigger for the likes of Heathcare Royalties to kick in with a big finance deal which by end Q2 will very much be needed to take next pipeline product(s) into clinic....otherwise why did we bring iHR's advisor on board...Have faith chaps...🤞😂

'Explore techniques to develop a spheroid co-culture model and characterise this co-culture model with CDX, PDX models and to empower the translation of pre|CISION®-peptide drug conjugates.'

Avacta

4 Dec 2025

'3:30 pm Optimising Spheroid Co-Cultures & PDX models to Empower the Translation of FAP-Enabled pre|CISION®-Peptide Drug Conjugates

Victoria Juskaite

Principal Scientist Therapeutics, Avacta Therapeutics

Highlighting the background of fibroblast activation protein (FAP)-enabled pre|CISION®-peptide drug conjugates (PDCs) and the rationale for model selection

Sharing best practices for developing co-cultures of tumour cells and human primary FAP+ fibroblasts to assess bystander activity of PDCs in physiologically relevant systems

Characterising PDCs using CDX, PDX models, and spheroid co-cultures to better understand their mechanism of action'

BV didn't CC say a while back when she first joined that she'd found something amazing sitting on the shelf hence the changes made to the pipeline...in so many words...

How many of these so called Research Notes are written by AI...how researched are the researchers these days or do they just ask AI to come up with the goods giving them more time to enjoy their long weekends...UK sirports are full gor a reason particularly on Fridays snd Mondays...😉

Nice late trades combined with the other 150000 at 16:04...

27-Nov-25 17:11:19 80.30 222,838 Unknown* 178.94k O

27-Nov-25 16:35:56 80.50 150,000 Unknown* 120.75k O

Very interesting trades today...lots of large trades broken down to itsy bitsy bite sizes...

Someone has been selling a shed load of shares....mmmm!! I wonder who the Institutional and HNWIs might have been and why sell on...mmm!!!

Guess it's quite an easy sell knowing that 1b data is definitely going to be released sometime between now and 30 December...and Zeus was the sole bookrunner. Not complaining...

Remember

PreCision can deliver some of the nastiest chemo drugs direct to the tumour site at greater doses than normal and avoiding vital organs with virtually no side effects.

For anyone undergoing chemo or about to or worried they or a family/friend may one day this is all they need to know. It's not chemo that worries people it's the horrendous side effects.

Next stage....even better....

PreCision+ can deliver some of the nastiest chemo drugs at greater doses than normal direct to the tumour site simultanteously with a companion drug avoiding other vital organs with virtually no side effects and preventing drug resistance.

Now that's something isn't it???

Don't get bogged down with the science...the message just needs to be plain and simple once safety is fully satisfied and once P2 data starts to come out...